Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for EMBC and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for EMBC and 80,000+ other tickers.
See exactly how EMBC's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for EMBC and 80,000+ other tickers.
Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in…
NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Embecta Corp. (NASDAQ: EMBC) between November 25, 2025 and May 4, 2026, inclusive (the "Class Period"), of the important August 17, 2026 lead plaintiff deadline.
NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Embecta Corp. (NASDAQ: EMBC) between November 25, 2025 and May 4, 2026, inclusive (the “Class Period”), of the important August 17, 2026 lead plaintiff deadline.
LOS ANGELES, July 22, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Embecta Corp. ("Embecta" or the "Company") (NASDAQ:EMBC). IF YOU SUFFERED A LOSS ON YOUR EMBECTA INVESTMENTS, CLICK HERE BEFORE AUGUST 17, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Embecta To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Embecta between November 25, 2025 and May 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - July 22, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Embecta Corp. ("Embecta" or the "Company") (NASDAQ: EMBC) and reminds investors of the August 17, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Important Information Regarding Section 20(a) Individual Liability Claims: Embecta's CEO and CFO Allegedly Certified Misleading Guidance That Cost Shareholders $5.35 Per Share NEW YORK, July 22, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP alerts investors in Embecta Corp. (NASDAQ: EMBC) of a pending securities class action naming two senior executives as individual defendants for their alleged role in disseminating misleading fiscal year 2026 guidance. Class Period: November 25, 2025 through May 4, 2026.